Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $91.89

Key Points

• Janux Therapeutics, Inc. has received an average rating of "Buy" from twelve analysts, with an average 12-month price objective of $91.89.
• Institutional investors own 75.39% of Janux's stock, with notable increases in stakes from GAMMA Investing LLC and US Bancorp DE, among others.
• Despite the optimistic ratings, Janux reported a loss in its latest earnings, missing the consensus estimate by $0.07 with an EPS of ($0.55).

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has received an average recommendation of "Buy" from the twelve analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $91.8889.

Separately, Raymond James Financial assumed coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price target on the stock.

Janux Therapeutics Price Performance

NASDAQ JANX traded down $0.30 during trading on Friday, hitting $24.67. The company's stock had a trading volume of 298,709 shares, compared to its average volume of 944,477. Janux Therapeutics has a fifty-two week low of $21.97 and a fifty-two week high of $71.71. The company has a market cap of $1.48 billion, a PE ratio of -13.63 and a beta of 2.86. The business's 50 day simple moving average is $24.62 and its 200-day simple moving average is $28.66.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.07). Analysts expect that Janux Therapeutics will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics during the fourth quarter worth approximately $59,000. GAMMA Investing LLC increased its position in Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company's stock worth $45,000 after buying an additional 1,574 shares during the period. US Bancorp DE increased its position in Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company's stock worth $47,000 after buying an additional 1,658 shares during the period. Finally, FNY Investment Advisers LLC increased its position in Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after buying an additional 2,425 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.